Nebivolol induces eNOS activation and NO-liberation in murine corpus cavernosum

Life Sciences

Volumn 80, Issue 26, 2007, Pages 2421-2427

  Reidenbach, C ^a,f   Schwinger, R H G ^b   Steinritz, D ^c   Kehe, K ^c   Thiermann, H ^c   Klotz, T ^d   Sommer, F ^e   Bloch, W ^a   Brixius, K ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b Klinikum Weiden   (Germany)

^c BUNDESWEHR INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (Germany)

^d Hospital Weiden   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

Author keywords

eNOS; Erectile dysfunction; Nebivolol

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DIAMINOFLUORESCEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUORESCEIN DERIVATIVE; METOPROLOL; NEBIVOLOL; NITRIC OXIDE; PROTEIN ANTIBODY; SMOOTH MUSCLE ACTIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DRUG SELECTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; IMMUNOFLUORESCENCE; MALE; NONHUMAN; PENIS ERECTION; SMOOTH MUSCLE FIBER; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BENZOPYRANS; ENZYME ACTIVATION; ERECTILE DYSFUNCTION; ETHANOLAMINES; FLUORESCENT ANTIBODY TECHNIQUE; FLUOROMETRY; MALE; MICE; MUSCLE, SMOOTH; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PENIS;

MURINAE;

EID: 34249752615     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.04.016     Document Type: Article

References (27)

1. Andersson K.E., and Wagner G. Physiology of penile erection. Physiological Reviews 75 1 (1995) 191-236
2. Bauer G.E., Baker J., Hunyor S.N., and Marshall P. Side effects of antihypertensive treatment; a placebo-controlled study. Clinical Science and Molecular Medicine 55 (1978) 341-344 (Suppl)
3. Bloch W., Klotz T., Sedlaczek P., Zumbe J., Engelmann U., and Addicks K. Evidence for the involvement of endothelial nitric oxide synthase from smooth muscle cells in the erectile function of the human corpus cavernosum. Urology Research 26 2 (1998) 129-135
4. Bloch W., Mehlhorn U., Krahwinkel A., Reiner M., Dittrich M., Schmidt A., and Addick K. Ischemia increases detectable endothelial nitric oxide synthase in rat and human myocardium. Nitric Oxide 5 4 (2001) 317-333
5. Boydak B., Nalbantgil S., Fici F., Nalbantgil I., Zoghi M., Ozerkan F., Tengiz I., Ercan E., Yilmaz H., Yoket U., and Onder R. A randomized comparison of the effects of nebivolol and atenolol with and without chlorthalidone on the sexual function of hypertensive men. Clinical Drug Investestigation 25 6 (2005) 409-416
6. Bremner A.D. Antihypertensive medication and quality of life - silent treatment of a silent killer. Cardiovascular Drugs and Therapy 16 (2002) 353-364
7. Brixius K., Bundkirchen A., Boelck B., Mehlhorn U., and Schwinger R.H.G. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. British Journal of Pharmacology 133 (2001) 1330-1338
8. 3-adrenoceptor induced eNOS activation in right atrial and left ventricular human myocardium. British Journal of Pharmacology 143 8 (2004) 1014-1022
9. Brixius K., Middeke M., Lichtenthal A., Jahn E., and Schwinger R.H.G. Nitric oxide, erectile dysfunction and β-blocker treatment (NOED-study): benefit of nebivolol versus metoprolol in hypertensive males. Clinical and Experimental Pharmacology and Physiology 34 4 (2007) 327-331
10. Chobanian A.V., Bakris G.L., and Black H.R. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
11. 3-adrenergic receptor activation via cyclic GMP - but not NO-dependent mechanism in human corpus cavernosum function. Proceedings of the National Academy of Sciences of the United States of America 100 (2003) 5531-5536
12. 3-adrenoceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation β-blocker nebivolol. Circulation 112 (2005) 1198-1205
13. Doumas M., Tsakiris A., Douma S., Grigorakis A., Papadopoulos A., Hounta A., Tsiodras S., Dimitriou D., and Giamarellou H. Beneficial effects of switching from β-blockers to nebivolol on the erectile function of hypertensive men. Asian Journal of Andrology 8 2 (2006) 177-182
14. Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 65 6 (2005) 773-786
15. Fogari R. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. European Journal of Clinical Pharmacology 58 3 (2002) 177-180
16. Fogari R., and Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men. Current Hypertension Reports 4 (2002) 202-210
17. Fogari R., Zoppi A., Lazzari P., Preti P., Mugellini A., Corradi L., and Lusardi P. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. American Journal of Hypertension 11 (1998) 1244-1347
18. Fogari R., Zoppi A., Poletti L., Marasi G., Mugellini A., and Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. American Journal of Hypertension 14 (2001) 27-31
19. Gao Y.S., Nagao T., Bond R.A., Janssens W.J., and Vanhoutte P.M. Nebivolol induces endothelium-dependent relaxation of canine coronary arteries. Journal of Cardiovascular Pharmacology 17 6 (1991) 956-959
20. Ignarro L.J., Byrns R.E., Trinh K., Sisodia M., and Buga G.M. Nebivolol: a selective beta(1)-adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide-and cyclic GMP-dependent mechanisms. Nitric Oxide 7 2 (2002) 75-82 (2002)
21. Itoh Y., Ma F.H., Hoshi H., Oka M., Noda K., Ukai Y., Kojima H., Nagano T., and Toda N. Determination and bio-imaging method for nitric oxide in biological specimens by diaminofluorescein fluorometry. Analytical Biochemistry 287 2 (2000) 203-209
22. Kojima H., Nakatsubo N., Kikuchi K., Kawahara S., Kirino Y., Nagoshi H., Hirata Y., and Nagano T. Detection and imaging of nitric oxide with novel fluorescent indicators: diaminofluoresceins. Analytical Chemistry 70 13 (1998) 2446-2453
23. NIH Consensus Conference Impotence. NIH Consensus Development Panel on Impotence. JAMA 270 (1993) 83-90
24. Shabsigh R., Perelman M.A., Lockhart D.C., Lue T.F., and Broderick G.A. Health issues of men: prevalence and correlates of erectile dysfunction. The Journal of Urology 174 (2005) 662-667
25. Suzuki H., Tominaga T., Kumagai H., and Saruta T. Effects of first-line antihypertensive agents on sexual function and sex hormones. Journal of Hypertension 6 (1988) S649-S651
26. Van Bortel L.M., Bulpit C.J., and Fici F. Quality of life and antihypertensive effect with nebivolol and Losartan. American Journal of Hypertension 18 (2005) 1060-1066
27. Weber M.A. The role of the new beta-blockers in treating cardiovascular disease. American Journal of Hypertension 18 (2005) 169S-176S